股票代码： 300972 股票简称：万辰生物 福建万辰生物科技股份有限公司 投资者关系活动记录表 编号：2022-001 | --- | --- | --- | --- | |-----------------------|------------------------------|----------------------------------------------------------|-------| | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | | 类别 | □ 媒体采访 √ | 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 参与公司 2021 | 年度网上业绩说明会的投资者 | | | 人员姓名 | | | | | 时间 | 2022 年 5 月 12 日 | 15:00~17:00 | | | 地点 | 全景网 " 投资者关系互动平台 | " （ https://ir.p5w.net | ） | | 上市公司接待人 员姓名 | 1 、董事、总经理 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥157,557,342.50, representing a 91.05% increase year-over-year[5] - Net profit attributable to shareholders was ¥35,760,840.39, a significant increase of 543.34% compared to the same period last year[5] - The basic earnings per share for the period was ¥0.2330, reflecting a 543.81% increase year-over-year[5] - The company reported a 44.82% increase in revenue for the year-to-date period, totaling ¥359,076,019.44[5] - The company's operating revenue for the first nine months of 2022 reached ¥359,076,019.44, representing a 44.82% increase compared to ¥247,947,794.28 in the same period of 2021, primarily due to higher sales prices and volumes of edible mushrooms[11] - Total operating revenue for the third quarter reached ¥359,076,019.44, an increase of 44.8% compared to ¥247,947,794.28 in the previous year[20] - Net profit for the period was ¥36,842,040.73, a significant recovery from a net loss of ¥20,837,651.13 in the same period last year[21] - The total comprehensive income for the period was CNY 36,842,040.73, compared to a loss of CNY 20,837,651.13 in the previous period[22] - Basic and diluted earnings per share were CNY 0.2445, an increase from a loss of CNY 0.1358 in the previous period[22] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥927,158,490.28, marking a 7.31% increase from the end of the previous year[5] - The company's total assets increased to ¥927,158,490.28, compared to ¥864,005,076.96 at the beginning of the year, marking a growth of 7.3%[18] - Current assets decreased to ¥205,218,743.97 from ¥302,388,611.64, a decline of 32.2%[17] - The company’s total liabilities increased by 42.63% to ¥92,390,919.45 due to increased short-term borrowings for operational needs[10] - The total liabilities increased to ¥266,710,561.39 from ¥210,469,188.80, an increase of 26.7%[18] - Short-term borrowings increased to ¥92,390,919.45 from ¥64,775,501.24, representing a rise of 42.5%[17] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥74,510,048.15, an increase of 64.72%[5] - The net cash flow from operating activities increased by 64.72% to ¥74,510,048.15, up from ¥45,233,363.79 in the previous year, mainly driven by increased cash inflows from product sales[11] - Cash inflow from operating activities totaled CNY 385,436,434.92, compared to CNY 289,532,927.81 in the previous period, indicating a year-over-year increase of about 33.2%[24] - Cash outflow from operating activities was CNY 310,926,386.77, compared to CNY 244,299,564.02 in the previous period, reflecting an increase of approximately 27.2%[25] - The net cash flow from investing activities was -CNY 193,491,075.19, worsening from -CNY 32,589,767.35 in the previous period[25] - Cash inflow from financing activities was CNY 110,450,000.00, down from CNY 304,060,500.00 in the previous period, a decrease of about 63.7%[25] - The net cash flow from financing activities was -CNY 13,805,773.56, compared to a positive flow of CNY 150,604,885.64 in the previous period[25] - The ending cash and cash equivalents balance was CNY 83,424,001.40, down from CNY 196,787,981.33 in the previous period[25] Expenses - The company reported a significant decrease in financial expenses by 44.36%, from ¥2,448,122.13 to ¥1,362,145.92, due to repayment of long-term loans and increased interest income from idle funds[11] - The company reported a decrease in financial expenses to ¥1,362,145.92 from ¥2,448,122.13, a reduction of 44.4%[21] - Research and development expenses decreased by 32.86% to ¥1,242,000.00, down from ¥1,850,000.00, mainly due to reduced outsourced R&D investments[11] - Research and development expenses were recorded at ¥1,242,000.00, down from ¥1,850,000.00, reflecting a decrease of 32.9%[20] - The company reported a significant increase in sales expenses by 166.28% to ¥4,424,315.70, compared to ¥1,661,503.39, mainly due to the establishment of new direct sales stores[11] Inventory and Production - Inventory levels rose by 32.66% to ¥73,456,013.62, attributed to the establishment of a new subsidiary[10] - Inventory levels rose to ¥73,456,013.62, up from ¥55,373,402.35, indicating a 32.7% increase[17] - The company is actively expanding its production capacity with ongoing projects, including a new facility for the production of edible fungi[10] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,009, with no preferred shareholders[13] - The top ten shareholders held a combined 56.67% of the company's shares, with the largest shareholder, Fujian Huanxi Grass Agricultural Development Co., Ltd., owning 26.68%[13] Other Information - The company received government subsidies amounting to ¥2,739,551.17 during the reporting period, contributing to its non-operating income[6] - Deferred income rose by 35.79% to ¥40,421,595.29, compared to ¥29,766,708.13 in the previous year, attributed to increased government subsidies related to assets[11] - The company experienced a 493.72% increase in net cash flow from investing activities, resulting in a net outflow of ¥193,491,075.19, compared to a net outflow of ¥32,589,767.35 in the previous year, primarily due to increased payments for project investments and financial products[11] - The report was not audited, indicating that the figures may be subject to further verification[26]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥201,518,676.94, representing a 21.78% increase compared to ¥165,479,069.82 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was ¥1,775,439.71, a significant turnaround from a loss of ¥12,771,341.51 in the previous year, marking a 113.90% improvement[18]. - Basic earnings per share increased to ¥0.0116 from a loss of ¥0.0832, reflecting a 113.94% improvement[18]. - The company reported a net profit after deducting non-recurring gains and losses of -¥7,270,402.86, an improvement of 74.16% from -¥28,134,029.97 in the previous year[18]. - The weighted average return on net assets was 0.27%, recovering from -3.24% in the same period last year[18]. - The company reported a gross profit margin of approximately 4.9% for the first half of 2022, compared to a negative margin in the previous year[145]. - The total comprehensive income for the first half of 2022 was ¥439,775,000.00[159]. - The company reported a profit distribution of ¥33,770,000.00 during the period[159]. Cash Flow and Investments - The net cash flow from operating activities decreased by 25.33% to ¥30,078,204.15 from ¥40,282,156.71 in the same period last year[18]. - The company reported a cash flow from investing activities net outflow of CNY -106,730,780.05, compared to CNY -20,862,748.59 in the same period last year, indicating increased investment activities[154]. - Cash flow from financing activities resulted in a net outflow of CNY -21,402,026.11, a decrease from a net inflow of CNY 183,455,296.75 in the first half of 2021, showing a shift in financing strategy[154]. - The company’s cash and cash equivalents at the end of the period were CNY 118,156,199.99, down from CNY 236,414,204.12 at the end of the first half of 2021, indicating a decrease in liquidity[154]. - The company’s investment activities resulted in a net cash outflow of ¥106.73 million, a significant increase of 411.59% compared to the previous year's outflow of ¥20.86 million[43]. Assets and Liabilities - Total assets at the end of the reporting period were ¥862,767,865.61, a slight decrease of 0.14% from ¥864,005,076.96 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company decreased by 4.90% to ¥621,541,327.87 from ¥653,535,888.16 at the end of the previous year[18]. - The company's total liabilities increased to CNY 164,055,473.09, up from CNY 111,338,913.55 in the previous year, indicating a growth of 47.2%[146]. - The company's short-term borrowings increased from CNY 64,775,501.24 to CNY 77,484,016.66, an increase of approximately 19.5%[140]. - The total equity attributable to shareholders decreased from CNY 653,535,888.16 to CNY 621,541,327.87, a decline of about 4.9%[140]. Production and Operations - The daily production capacity of edible mushrooms reached 243.5 tons, with specific capacities of 204 tons for enoki mushrooms, 28 tons for king oyster mushrooms, and 11.5 tons for velvet mushrooms[26]. - The company focuses on the research and development of fresh edible mushrooms, utilizing modern biotechnology and factory-based cultivation methods[26]. - The company has established production bases in Fujian Zhangzhou and Jiangsu Nanjing, which are key markets for mushroom production and consumption in China[38]. - The company has implemented a liquid strain technology for enoki mushroom production, which is expected to improve production efficiency and profitability[37]. - The company is expanding its production of various mushroom products, particularly focusing on enoki mushrooms, to diversify and mitigate seasonal impacts on performance[75]. Research and Development - Research and development expenses increased significantly by 333.33% to ¥650,000, up from ¥150,000 in the previous year, primarily due to increased external research and development costs[43]. - The company obtained 2 invention patents and 6 utility model patents during the reporting period, enhancing its intellectual property portfolio[36]. - The company has established partnerships with universities to cultivate superior new strains of mushrooms, contributing to stable production and reduced costs[64]. - The company is investing in technology innovation, focusing on strain selection and production process improvements, which are essential for maintaining competitive advantages in the industry[77]. Market and Sales - The company’s products are primarily sold in East China, South China, and Central China, with expansion into Southwest, Northwest, North, and Northeast regions[26]. - The company has a strong brand presence in South China and East China, with plans to expand into Central and North China markets[40]. - The company did not experience any sales returns during the reporting period, indicating strong product demand[36]. - Revenue from golden needle mushrooms was 158,342,539.20, with a year-on-year increase of 22.85%, while the gross margin was 3.66%, up 13.93% from the previous year[45]. Risk Management and Compliance - The company emphasizes the importance of risk awareness and rational investment in its forward-looking statements[3]. - The company faces risks from intensified market competition due to rapid capacity expansion in the edible mushroom industry, which may lead to significant price fluctuations and impact profitability[74]. - The company has complied with regulatory requirements for the management and disclosure of raised funds, ensuring transparency and accuracy[63]. - The company is not classified as a key pollutant discharge unit and did not face any administrative penalties for environmental issues during the reporting period[89]. Shareholder and Corporate Governance - The annual shareholders' meeting had a participation rate of 55.10% on May 16, 2022[83]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[85]. - The company has a total of 153,500,000 shares, with 36,441,000 shares released from restrictions, accounting for 23.74% of the total share capital after issuance[119]. - The largest shareholder, Fujian Huxiu Grass Agricultural Development Co., Ltd., holds 26.68% of the shares, totaling 40,949,000 shares[123]. Financial Reporting and Accounting - The semi-annual financial report has not been audited[98]. - The company has not reported any changes in accounting policies or prior period errors for the current reporting period[168]. - The financial statements are prepared based on the assumption of going concern, with no significant doubts about the company's ability to continue operations[176]. - The company has complied with the relevant accounting standards, ensuring that the financial statements reflect the true financial position as of June 30, 2022[178].

Revenue and Profit - The company's revenue for Q1 2022 was ¥116,629,969.32, representing a 12.98% increase compared to ¥103,230,720.80 in the same period last year[4] - Net profit attributable to shareholders was ¥24,323,027.38, a 4.85% increase from ¥23,197,275.35 year-on-year[4] - Net profit for Q1 2022 reached CNY 24,323,027.38, compared to CNY 23,197,275.35 in the same period last year, reflecting a growth of approximately 4.83%[24] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.16, down from CNY 0.20 in the previous year[25] Cash Flow and Investments - The company's cash flow from operating activities decreased by 29.73% to ¥42,803,710.97 compared to ¥60,909,105.92 in the same period last year[4] - The net cash flow from investment activities was significantly negative at -¥135,255,212.17, a 4946.17% increase in outflow compared to -¥2,680,354.46 in the previous year[11] - The company reported a total investment cash outflow of 336,118,474.55 CNY, primarily for the acquisition of fixed assets and other investments[28] - The total cash inflow from financing activities was 37,700,000.00 CNY, while the cash outflow was 50,909,627.60 CNY, resulting in a net cash flow of -13,209,627.60 CNY[28] - The company's cash and cash equivalents decreased by 48.87% to ¥110,549,673.20, primarily due to investments in financial products[9] Assets and Liabilities - Total assets increased by 2.04% to ¥881,645,765.81 from ¥864,005,076.96 at the end of the previous year[4] - Total liabilities as of the end of Q1 2022 were CNY 203,786,850.27, slightly down from CNY 210,469,188.80 at the end of the previous period[22] - Total equity attributable to shareholders of the parent company increased to CNY 677,858,915.54 from CNY 653,535,888.16 year-on-year[22] Operational Performance - Total operating costs for Q1 2022 amounted to CNY 100,772,954.40, up from CNY 80,864,587.36 year-on-year[23] - Cash inflow from sales of goods and services was CNY 119,507,370.86, compared to CNY 107,079,033.35 in the previous year[26] - The company reported other income of CNY 7,806,859.20, significantly higher than CNY 1,093,866.97 in the previous period[23] Shareholder Information - The company reported a total of 115,125,000 restricted shares, with no changes during the period[17] - The company has a significant number of shareholders, with the top ten holding a total of 1,045,969 shares by UBS AG[14] - The company plans to release restricted shares on April 19, 2024, for several major shareholders, including Fujian Huanxi Grass Agricultural Development Co., Ltd. with 40,949,000 shares[16] Other Financial Metrics - The net profit after deducting non-recurring gains and losses decreased by 29.29% to ¥15,821,381.19 from ¥22,375,424.46 in the previous year[4] - The company’s weighted average return on equity decreased to 3.65% from 5.63% year-on-year[4] - The total current assets were reported at CNY 295,651,445.05, down from CNY 302,388,611.64, indicating a decrease of about 2.4%[20] - Inventory levels increased slightly to CNY 56,506,798.49 from CNY 55,373,402.35, reflecting a growth of approximately 2.1%[20] - The company's fixed assets decreased to CNY 465,255,712.65 from CNY 471,861,707.86, a reduction of about 1.4%[20] - Short-term borrowings rose to CNY 67,472,297.92 from CNY 64,775,501.24, marking an increase of approximately 4.2%[20] - Accounts payable decreased slightly to CNY 57,780,771.18 from CNY 59,680,460.70, a decline of about 3.2%[20] Audit Status - The report for the first quarter was not audited, indicating that the figures may be subject to change[29]

Financial Performance - The company's annual report indicates a year-on-year decline in performance, with specific reasons detailed in the management discussion section[5]. - The company's operating revenue for 2021 was CNY 425,520,717.94, a decrease of 5.44% compared to CNY 449,983,599.12 in 2020[16]. - The net profit attributable to shareholders for 2021 was CNY 24,279,165.30, representing a significant decline of 74.74% from CNY 96,130,282.50 in 2020[16]. - The net profit after deducting non-recurring gains and losses was CNY 3,887,562.99, down 95.73% from CNY 91,041,364.50 in 2020[16]. - The net cash flow from operating activities decreased by 36.75% to CNY 98,823,175.20 from CNY 156,241,037.41 in 2020[16]. - The total assets at the end of 2021 increased by 31.25% to CNY 864,005,076.96 compared to CNY 658,267,502.95 at the end of 2020[16]. - The net assets attributable to shareholders rose by 63.12% to CNY 653,535,888.16 from CNY 400,653,822.86 in 2020[16]. - The company achieved a revenue of CNY 425.52 million in the reporting period, a decrease of 5.44% year-on-year[40]. - The net profit attributable to shareholders was CNY 24.28 million, down 74.74% compared to the previous year[40]. Research and Development - The company reported a significant focus on R&D for new products and technologies, although specific figures were not disclosed in the provided content[5]. - The company has obtained 5 new utility model patents during the reporting period, indicating a commitment to innovation and intellectual property development[47]. - The company’s R&D investment amounted to ¥23,445,379.42 in 2021, representing 5.51% of operating revenue, up from 2.77% in 2020[72]. - The number of R&D personnel increased by 68.75% to 27, with a significant rise in the number of bachelor's degree holders from 9 to 25[72]. - The R&D projects include the breeding of new varieties of golden needle mushrooms and the development of factory cultivation techniques for various mushroom species[70]. - The company aims to develop new strains of mushrooms with independent intellectual property rights, enhancing its competitive edge in the market[70]. - The company is focusing on research and development for edible mushroom breeding and process optimization, aiming to reduce production costs and improve product quality[104]. Market Expansion and Strategy - The company is actively exploring market expansion opportunities, particularly in the biotechnology sector, although specific metrics were not provided[5]. - The company operates in the edible mushroom industry, which is experiencing growing demand due to increasing consumer health awareness and income levels[26]. - The company operates two major production bases located in Fujian Zhangzhou and Jiangsu Nanjing, primarily serving East, South, and Central China, with expansion into Southwest, Northwest, North, and Northeast regions[32]. - The company is developing a new research center for edible mushroom breeding and process development to enhance its R&D capabilities[55]. - The company plans to expand its production capacity for king oyster mushrooms from an initial 21,000 tons to 53,000 tons, enhancing market competitiveness and reducing production costs[96][97]. - The company aims to strengthen market expansion in Southwest and North China, targeting small and medium-sized cities to enhance sales networks[102]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[129]. Financial Management and Governance - The company maintains a commitment to transparency and accuracy in its financial reporting, as stated by its management[4]. - The company has established a dedicated investor relations team to facilitate communication with shareholders[14]. - The company has a complete production system and independent financial decision-making capabilities, ensuring operational independence from its controlling shareholder[117]. - The company has established a governance structure that includes a board of directors, supervisory board, and management team, ensuring clear responsibilities and coordination[115]. - The company has implemented refined management practices to control and reduce production costs[54]. - The company has established measures to ensure compliance with public commitments and to address any potential losses to investors[197]. Environmental and Social Responsibility - The company emphasizes its commitment to social responsibility and maintaining good relationships with stakeholders, contributing to stable and healthy development[165]. - The company has established a hazardous waste storage facility and is taking corrective actions as required by regulatory authorities[164]. - The company has not disclosed any additional environmental information, citing no relevant reasons[164]. - The company has fulfilled its commitments regarding stock transfer restrictions, ensuring compliance with lock-up periods following its IPO[168]. Future Outlook - Future plans and profit forecasts are mentioned, but they are subject to risks that the company has outlined in the report[5]. - The company plans to implement a new digital marketing strategy aimed at increasing brand awareness and customer engagement by 40%[129]. - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues to reach approximately 1.65 billion RMB[175]. - The company has projected a revenue growth of 25% for the next fiscal year, aiming for a target revenue of 1.875 billion RMB[171]. - The management emphasized the importance of maintaining shareholder value and committed to transparent communication regarding future strategies[192]. Shareholder Engagement - The profit distribution plan approved by the board proposes a cash dividend of 2.20 yuan per 10 shares (tax included) for all shareholders[5]. - The company proposed a cash dividend of CNY 2.20 per 10 shares, resulting in a total cash dividend amount of CNY 33,770,000.00, which represents 100% of the distributable profit[155]. - The company held its annual shareholder meeting on May 20, 2021, with a participation rate of 55.09%[120]. - The company conducted its first extraordinary shareholder meeting on August 16, 2021, with a participation rate of 55.11%[120].

Financial Performance - The company's operating revenue for Q3 2021 was ¥82,468,724.46, a decrease of 25.60% compared to the same period last year[3] - The net profit attributable to shareholders was -¥8,066,309.62, representing a decline of 139.16% year-on-year[3] - The net cash flow from operating activities for the year-to-date was ¥45,233,363.79, down 60.35% compared to the previous year[3] - Total operating revenue for the current period is CNY 247,947,794.28, a decrease from CNY 327,144,354.11 in the previous period[21] - The net profit for the current period is a loss of CNY 20,837,651.13, compared to a net profit of CNY 71,338,382.32 in the previous period[22] - The total comprehensive income for the current period is a loss of CNY 20,837,651.13, contrasting with a comprehensive income of CNY 71,338,382.32 in the previous period[23] - The basic and diluted earnings per share for the current period are both -CNY 0.14, compared to CNY 0.62 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period reached ¥811,396,490.53, an increase of 23.26% from the end of the previous year[3] - The company's current assets reached CNY 258,756,671.57, significantly up from CNY 93,128,867.49 at the end of 2020, indicating a growth of about 177.5%[17] - The cash and cash equivalents increased to CNY 96,787,981.33 from CNY 33,539,499.25, marking a rise of approximately 188.5%[17] - Accounts receivable rose to CNY 3,177,045.85, compared to CNY 2,367,326.39 at the end of 2020, reflecting an increase of about 34.2%[17] - The total liabilities decreased to CNY 202,977,418.80 from CNY 257,613,680.09, a reduction of approximately 21.2%[19] - The company has no long-term borrowings as of the end of the reporting period, reflecting a 100% decrease in long-term debt[9] - The company reported a decrease in short-term borrowings to CNY 70,975,354.15 from CNY 88,058,208.33, a decline of approximately 19.5%[19] Equity and Shareholder Information - The company's equity attributable to shareholders increased by 51.86% to ¥608,419,071.73 compared to the previous year[4] - The company's equity attributable to shareholders increased to CNY 608,419,071.73 from CNY 400,653,822.86, representing a growth of about 52%[19] - The company issued 38.375 million shares in April 2021, raising net funds of ¥228,602,900, contributing to the increase in total assets and equity[10] Research and Development - Research and development expenses surged by 877.80% to ¥1,850,000.00 due to increased outsourcing for collaborative R&D[9] - Research and development expenses increased significantly to CNY 1,850,000.00 from CNY 189,200.00 in the previous period[22] Income and Costs - The gross profit margin and net profit were significantly impacted by a decline in product sales prices and an increase in raw material costs[9] - Total operating costs increased to CNY 283,869,098.02 from CNY 258,874,817.18, with operating costs specifically rising from CNY 233,855,538.57 to CNY 257,654,857.79[22] Other Income and Cash Flow - The company reported a significant increase in other income, which rose by 374.99% to ¥17,183,336.65, primarily due to increased government subsidies[9] - The cash flow from operating activities generated a net cash flow of CNY 45,233,363.79, down from CNY 114,095,071.40 in the previous period[25] - The net cash flow from financing activities was CNY 150,604,885.64, compared to a negative cash flow of CNY 78,221,562.30 in the previous period[26] - Cash and cash equivalents at the end of the period increased to CNY 196,787,981.33 from CNY 23,883,765.19 in the previous period[26] - The company raised CNY 233,160,500.00 from investment activities during the current period[26] Reporting and Compliance - The third quarter report of Fujian Wancheng Biotechnology Co., Ltd. has not been audited[29] - The board of directors has confirmed the unaudited status of the third quarter report[29] - The company has implemented new leasing standards starting from 2021, with retrospective adjustments to prior comparative data[29] - The report is part of the company's ongoing compliance with financial reporting standards[29] Future Outlook and Strategy - Future outlook and performance guidance are not mentioned in the document[29] - No new products or technologies are discussed in the document[29] - There are no details on market expansion or mergers and acquisitions provided[29] - The document does not outline any new strategies[29] - There are no specific financial performance metrics or user data provided in the document[29] - The company has not disclosed any revenue figures or growth percentages[29]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥165,479,069.82, a decrease of 23.50% compared to ¥216,300,504.86 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was -¥12,771,341.51, representing a decline of 125.17% from ¥50,737,800.72 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥28,134,029.97, down 158.06% from ¥48,459,654.73 in the same period last year[21]. - The net cash flow from operating activities was ¥40,282,156.71, a decrease of 45.69% compared to ¥74,169,347.49 in the previous year[21]. - The basic earnings per share were -¥0.08, a decrease of 118.18% from ¥0.44 in the same period last year[21]. - The diluted earnings per share were also -¥0.08, reflecting the same decline of 118.18% from ¥0.44 in the previous year[21]. - The weighted average return on net assets was -3.24%, down 17.85% from 14.61% in the previous year[21]. - The company reported a net profit of -21,834,591 CNY for the first half of 2021, indicating a significant loss[80]. - The company reported a total revenue from sales of goods and services of CNY 164,207,153.27 for the first half of 2021, compared to CNY 215,047,803.50 in the same period of 2020[171]. Assets and Liabilities - The total assets at the end of the reporting period were ¥848,209,923.54, an increase of 28.85% from ¥658,267,502.95 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 53.87% to ¥616,485,381.35 from ¥400,653,822.86 at the end of the previous year[21]. - The company's total assets as of June 30, 2021, amounted to CNY 848,209,923.54, an increase from CNY 658,267,502.95 at the end of 2020, representing a growth of approximately 28.9%[157]. - Total liabilities decreased to CNY 231,724,542.19 from CNY 257,613,680.09, showing a reduction of about 10.1%[156]. - The company's equity attributable to shareholders rose to CNY 616,485,381.35 from CNY 400,653,822.86, marking an increase of approximately 54%[157]. Production and Operations - The company’s daily production capacity for edible mushrooms reached 255 tons, with 227 tons for enoki mushrooms and 28 tons for king oyster mushrooms[29]. - The company operates two production bases located in Fujian and Jiangsu, primarily serving East, South, and Central China, with some reach to Southwest, Northwest, North, and Northeast regions[29]. - The company has established two major production bases in Fujian Zhangzhou and Jiangsu Nanjing, which are strategically located in key consumption markets, enhancing brand influence and sales reach[49]. - The company has a strong scale advantage in the domestic factory-based edible mushroom production, with a centralized production model that reduces costs and enhances output stability[50]. - The company has diversified its product offerings, including four sub-varieties of edible mushrooms, which helps mitigate market risks associated with single product dependency[49]. Market Conditions - The decline in revenue and profit was primarily due to a decrease in the selling prices of the company's main products, enoki mushrooms and king oyster mushrooms[29]. - The edible mushroom market is experiencing seasonal price fluctuations, impacting the company's gross margin and overall performance[28]. - Seasonal fluctuations in sales prices of edible mushrooms can impact the company's gross margin and overall performance, with lower revenue typically seen in the first half of the year[81]. - The company faces risks from intensified market competition due to rapid capacity expansion in the edible mushroom industry, which could lead to significant price fluctuations[81]. Research and Development - The company is focused on the research and development of fresh edible mushrooms, responding to the growing market demand driven by health consciousness and consumption upgrades[28]. - The company has established a strong focus on R&D, collaborating with institutions like Fujian Agriculture and Forestry University to develop new technologies and products[41]. - The company is investing in technological innovation, particularly in strain selection and production process stability, to enhance its competitive edge[86]. - The company emphasizes the importance of food safety, utilizing fully automated processes for sowing, sterilization, and modular cultivation management to minimize contamination risks[88]. Financial Management - The company plans not to distribute cash dividends or issue bonus shares[7]. - The company has implemented a comprehensive management system for biological assets, ensuring accurate accounting and inventory control through monthly physical counts[42]. - The company has a strong focus on cost control and improving production efficiency to counteract potential declines in gross margin due to rising costs[85]. - The company has reported a significant increase in cash and cash equivalents, rising by 9,053.29% to ¥202,874,704.87 from ¥2,216,412.82[55]. Shareholder Information - The company issued 38.375 million shares at a price of RMB 7.19 per share, raising a total of RMB 275.91625 million, with a net amount of RMB 228.6029 million after deducting fees[67]. - The total number of ordinary shareholders at the end of the reporting period is 25,237[136]. - The largest shareholder, Fujian Huanxi Grass Agricultural Development Co., Ltd., holds 26.68% of the shares[136]. - The second largest shareholder, Zhangzhou Jinwancheng Investment Co., Ltd., holds 19.50% of the shares[136]. Compliance and Governance - The company has maintained a strong focus on corporate governance and compliance with relevant laws and regulations to ensure stable and healthy development[100]. - The company's half-year financial report has not been audited, indicating that the financial results are still subject to review[105]. - There have been no major litigation or arbitration matters reported during the period, reflecting a stable legal standing for the company[107].

股票代码：300972 股票简称：万辰生物 公告编号：2021-028 福建万辰生物科技股份有限公司 关于参加 2021 年度福建上市公司投资者网上集体接待日活动 暨召开 2020 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流，使广大投资者能更深入全面地了解福建 万辰生物科技股份有限公司（以下简称"公司"）情况，公司将参加由福建证监 局与福建省上市公司协会、深圳市全景网络有限公司举办的"2021 年度福建上市 公司投资者网上集体接待日活动"暨召开"2020 年度业绩说明会"。现将有关事项 公告如下： 本次投资者网上集体接待日活动暨 2020 年度业绩说明会将通过深圳市全景 网络有限公司提供的网上平台采取网络远程的方式进行，投资者可以登录"全景 网投资者关系互动平台（http://ir.p5w.net）"参与，网上互动交流时间为 2021 年 5 月 14 日（星期五）15:30 至 17:00。 出席会议的人员有：公司总经理王丽卿女士、董事会秘书兼财务总监蔡冬娜 女士。 为充分尊重投资者、提升交流的针对 ...

Financial Performance - The company's revenue for Q1 2021 was ¥103,230,720.80, a decrease of 23.96% compared to ¥135,754,787.86 in the same period last year[8] - Net profit attributable to shareholders was ¥23,197,275.35, down 57.23% from ¥54,232,605.00 year-on-year[8] - The basic earnings per share decreased to ¥0.20, a decline of 57.45% compared to ¥0.47 in the previous year[8] - Operating revenue for Q1 2021 was ¥10,323.07 million, a decline of 23.96% year-over-year, with net profit down 57.23% to ¥2,319.73 million[20] - Total operating revenue for Q1 2021 was CNY 103,230,720.80, a decrease from CNY 135,754,787.86 in the previous period[46] - Net profit for Q1 2021 was CNY 23,197,275.35, down from CNY 54,232,605.00 in the same period last year, reflecting a decline of approximately 57.3%[48] - Operating profit decreased to CNY 13,721,705.97 from CNY 25,627,873.44 year-over-year[52] - The company’s total comprehensive income for the period was CNY 13,452,038.23, down from CNY 25,626,293.40 in the previous year[53] Assets and Liabilities - Total assets at the end of the reporting period were ¥634,337,263.90, a decrease of 3.64% from ¥658,267,502.95 at the end of the previous year[8] - Total assets as of March 31, 2021, amounted to CNY 423,917,367.17, a decrease from CNY 442,006,667.42 at the end of 2020[44] - Total liabilities decreased to CNY 109,144,294.14 from CNY 140,685,632.62, showing a reduction of approximately 22.4%[44] - Current liabilities decreased from ¥212,455,095.77 to ¥175,183,345.33, a reduction of about 17.5%[40] - Long-term borrowings decreased from ¥29,996,600.00 to ¥14,998,300.00, a decrease of approximately 50%[40] - The total liabilities decreased from ¥257,613,680.09 to ¥210,486,165.69, a reduction of approximately 18.3%[40] Cash Flow - The net cash flow from operating activities was ¥60,909,105.92, showing a slight increase of 0.59% compared to ¥60,548,945.21 in the same period last year[8] - Cash flow from operating activities was CNY 60,909,105.92, slightly up from CNY 60,548,945.21 year-over-year[56] - Total cash inflow from operating activities was ¥77,100,410.38, compared to ¥69,786,847.01 in the prior period, indicating an increase of about 10.4%[58] - Cash outflow from operating activities decreased to ¥43,150,808.35 from ¥46,191,444.26, reflecting a reduction of approximately 6.5%[58] - The company incurred a net cash outflow from financing activities of CNY -68,353,669.66, compared to a net inflow of CNY 2,795,123.04 in the previous year[57] - The net cash flow from financing activities decreased significantly to -¥48,616,687.49 from ¥37,133,709.44, indicating a negative shift in financing[60] Shareholder Information - The company had a total of 88 common shareholders at the end of the reporting period[12] - The largest shareholder, Fujian Huanxi Grass Agricultural Development Co., Ltd., held 35.57% of the shares, totaling 40,949,000 shares[12] Operational Efficiency - Accounts receivable dropped by 44.71% to ¥1,308,927.57 as the company collected outstanding payments from customers[17] - Sales expenses decreased by 53.10% to ¥409,812.73, primarily due to reduced advertising and adjustments in transportation costs[18] - The company reported a significant reduction in financial expenses by 46.71% to ¥1,421,554.24, attributed to decreased short-term and long-term borrowings[18] - Contract liabilities increased by 65.67% to ¥6,981,288.91, reflecting prepayments from distributors for goods not yet delivered[17] Market and Strategic Outlook - The company faced risks from intensified market competition and seasonal price fluctuations in the edible mushroom industry, which could impact profitability[24][25] - The company plans to diversify its product offerings and expand into overseas markets to mitigate seasonal sales fluctuations[25] - The first five suppliers accounted for 39.17% of total purchases in Q1 2021, up from 36.63% in the same period last year, indicating a stable supplier relationship[21] Research and Development - The company is focusing on technological innovation in strain selection and production processes, which involves significant R&D investment and carries high innovation risks[27] - The company has established a talent cultivation system to enhance its R&D capabilities and improve the success rate of technological innovations[27] Food Safety - The company emphasizes the importance of food safety and has implemented measures to mitigate risks associated with contamination during production and distribution[28] Miscellaneous - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[62] - The company has not applied the new leasing standards for the current financial reporting period[61]

Financial Performance - The company's operating revenue for 2020 was CNY 449,983,599.12, a decrease of 0.21% compared to CNY 450,909,279.18 in 2019[16] - The net profit attributable to shareholders for 2020 was CNY 96,130,282.50, representing an increase of 4.28% from CNY 92,187,595.43 in 2019[16] - The net profit after deducting non-recurring gains and losses was CNY 91,041,364.50, a slight increase of 0.25% compared to CNY 90,811,709.87 in 2019[16] - The net cash flow from operating activities decreased by 11.87% to CNY 156,241,037.41 from CNY 177,279,691.75 in 2019[16] - The basic earnings per share for 2020 was CNY 0.84, up 5.00% from CNY 0.80 in 2019[16] - The total assets at the end of 2020 were CNY 658,267,502.95, a slight increase of 0.40% from CNY 655,625,011.61 at the end of 2019[16] - The net assets attributable to shareholders increased by 16.19% to CNY 400,653,822.86 from CNY 344,817,290.36 at the end of 2019[16] - The weighted average return on net assets for 2020 was 26.51%, an increase of 1.05% from 25.46% in 2019[16] Revenue Breakdown - Total revenue for the year was approximately CNY 450 million, with a quarterly breakdown of CNY 135.75 million in Q1, CNY 80.55 million in Q2, CNY 110.84 million in Q3, and CNY 122.84 million in Q4[19] - Net profit attributable to shareholders was CNY 54.23 million in Q1, a loss of CNY 3.49 million in Q2, CNY 20.60 million in Q3, and CNY 24.79 million in Q4, resulting in a total net profit of CNY 95.13 million for the year[19] - The company reported a net cash flow from operating activities of CNY 60.55 million in Q1, CNY 13.62 million in Q2, CNY 39.93 million in Q3, and CNY 42.15 million in Q4, totaling CNY 156.25 million for the year[19] Production Capacity and Operations - The company has a daily production capacity of 255 tons of edible mushrooms, with 227 tons for enoki mushrooms and 28 tons for shimeji mushrooms, ranking among the top in the industry[26] - The company operates two major production bases located in Fujian and Jiangsu, primarily serving markets in East, South, and Central China, with expansion into Southwest, Northwest, North, and Northeast regions[26] - The company completed the expansion project for the king oyster mushroom production facility in September, enhancing production capacity and product variety[43] Research and Development - The company focuses on the research and development of fresh edible mushrooms, utilizing modern biotechnology and factory-based production methods to ensure quality and safety[26] - The company has fully adopted liquid strain technology in the production of enoki mushrooms, which is a significant competitive advantage[34] - The company is actively promoting liquid strain technology to improve the production efficiency of the king oyster mushroom, thereby enhancing profitability[34] - Research and development expenses increased by 150.70% to ¥429,200.00, primarily due to increased costs associated with external R&D collaborations[56] - The total R&D investment amounted to ¥12,458,209.18, which is 2.77% of the operating revenue[59] Market and Sales Strategy - The company has established a sales network covering nearly 20 provinces and regions, with over 60 stable partnerships with distributors[38] - The company focused on optimizing marketing strategies, expanding sales channels, and enhancing cooperation with major supermarkets[43] - The sales of king oyster mushrooms accounted for 82.99% of total revenue, increasing by 2.81% year-on-year, while sales of white mushrooms decreased by 24.54%[47] Environmental and Social Responsibility - The company emphasizes environmental sustainability by using agricultural by-products as cultivation materials and ensuring waste recycling in its production processes[26] - The company maintained a strong commitment to social responsibility, actively participating in pandemic relief efforts and ensuring the supply of fresh produce[44] - The company donated a total of 86.6 tons of fresh enoki mushrooms to support the "vegetable basket" project during the pandemic[196] - The company was listed as one of the first national key guarantee enterprises for epidemic prevention and control by several government ministries in early February[196] Financial Management and Commitments - The company plans not to distribute cash dividends or issue bonus shares[5] - The company has a clear profit distribution policy that complies with its articles of association and has been transparently executed[90] - The company plans to retain undistributed profits for future business expansion needs, indicating a focus on long-term growth[92] - The company reported a commitment to strictly adhere to the profit distribution policy as per its articles of association, ensuring compliance with the profit distribution decision-making process[130] Compliance and Regulatory Matters - The company confirmed the accuracy and completeness of the prospectus, stating that there are no false records or misleading statements[123] - The company will ensure compliance with all relevant laws and regulations during the share reduction process[107] - The company has committed to minimizing investor losses and protecting their interests through various measures[156] - The company will publicly disclose any failure to fulfill commitments and provide specific reasons to shareholders and the public[154] Risks and Challenges - The company faces risks from intensified market competition and seasonal price fluctuations, which could impact profitability[81][82] - The company acknowledges the high risk associated with technological innovation in mushroom cultivation and production processes[84] - The company is committed to cost management and efficiency improvements to counteract potential declines in gross margin[84]